Flukicide efficacy against Fasciola hepatica of Triclabendazole and Nitroxynil in cattle of the central valley of Chile / Avaliação da eficácia de triclabendazol e nitroxinil para o tratamento da infeção por Fasciola hepatica em bovinos do Vale Central do Chile

Abstract On a farm with permanent history of fasciolasis a study was performed aimed to know the efficacy of triclabendazole (TCBZ) and then to contrast with that of nitroxynil. Thirty-nine cattle naturally infected with Fasciola hepatica were randomly allocated into 4 experimental groups: Group 1 (control) was left untreated. Group 2 was treated with of 12 mg/kg body weight (bw) of TCBZ by oral route. Group 3 treated with 24 mg/kg bw TCBZ orally. Group 4 was treated with 10 mg/kg bw of nitroxynil subcutaneously. The anthelmintic efficacy was calculated as the percentage of reduction in faecal egg count (FEC) at 14 and 28 d post-treatment. Results indicated that there were no significant differences in the percentage of FEC reduction between control group and the groups treated with 12 or 24 mg/kg of TCBZ. On the contrary, the treatment with nitroxinyl significantly reduced the FEC and decreased the percentage of positive animals. In conclusion, Fasciola hepatica is reported for first time as resistant to TCBZ in Chile, which highlights the need of rotating drugs and assessing the efficacy of the administered drug in order to avoid the selection of resistant worms.

Resumo Em uma fazenda com histórico de fasciolose permanente, foi realizado um estudo com o objetivo de conhecer a eficácia do triclabendazol (TCBZ) e depois contrastar com o do nitroxinil. Trinta e nove bovinos naturalmente infectados com Fasciola hepatica foram distribuídos aleatoriamente em 4 grupos experimentais: Grupo 1 (controle), sem tratamento. O grupo 2 foi tratado com 12 mg/kg de peso vivo (PV) do TCBZ por via oral (VO). Grupo 3 tratado com 24 mg/kg de PV TCBZ por VO. O grupo 4 foi tratado com 10 mg /kg de PV Nitroxinil via subcutânea. A eficácia anti-helmíntica foi calculada comparando a percentagem de redução na contagem de ovos fecais (FEC) 14 e 28 dias pós tratamento. Não houve diferença significativa na porcentagem de redução FEC entre o grupo controle e os grupos tratados com 12 ou 24 mg/kg de TCBZ. Entretanto, o tratamento com nitroxinil reduziu significativamente o FEC e diminuiu a porcentagem de animais positivos. Em conclusão, a Fasciola hepatica é relatada pela primeira vez como resistente ao TCBZ no Chile, o que destaca a necessidade de realizar uma rotação em relação aos medicamentos anti-helmínticos e avaliar a eficácia do mesmo, a fim de evitar a seleção de vermes resistentes.

Microscopic alterations in Fasciola hepatica from sheep treated with albendazole / Alterações microscópicas em Fasciola hepatica de ovelhas tratadas com albendazol

Abstract Currently, albendazole is one of the most commonly used drugs because of its affordability. The objective was to evaluate the histopathology of Fasciola hepatica specimens. For this, the efficacy test was performed on sheep treated with albendazole at the dose recommended for F. hepatica, in which the helminths recovered at necropsy were counted and separated for histology. Spermatogenic cells from parasites recovered from treated and control sheep were examined by microscopy. The fecal egg-count reduction test revealed 97.06% efficacy of albendazole in the treatment of F. hepatica. Changes in testicular tubule cells started 48 hours after treatment and became evident within 72 hours, at which point it became difficult to identify cell types. Primary and secondary spermatogonia became increasingly rare and intercellular vacuolization was more evident. Signs of apoptosis, with pycnotic nuclei and evidence of keriorrexia were observed at all times. Cell debris was identified 96 hours after treatment. The results indicated that parasitic spermatogenesis was severely affected by albendazole and demonstrated the importance of the use of histopathology for the diagnosis of therapeutic efficacy in field strains.

Resumo Na atualidade, o albendazol é uma das drogas mais usadas devido à sua acessibilidade econômica. O objetivo foi avaliar a histopatologia dos espécimes de Fasciola hepatica. Para isso, foi realizado o teste de eficácia em ovinos tratados com albendazol na dose recomendada para Fasciola hepatica, no qual os helmintos recuperados em necropsia foram contabilizados e separados para histologia. As células espermatogênicas de parasitas recuperados de ovinos tratados e controle foram examinadas por microscopia. O teste de redução de ovos por grama de fezes revelou 97,06% de eficácia do albendazol no tratamento de F. hepatica. As alterações nas células dos túbulos testiculares iniciaram-se 48 horas após o tratamento e tornaram-se evidentes em 72 horas, altura em que tornou-se difícil identificar os tipos de células. As espermatogônias primárias e secundárias tornaram-se cada vez mais raras e a vacuolização intercelular foi mais evidente. Sinais de apoptose, com núcleos picnóticos e evidência de cariorrexia foram observados em todos os momentos. Os detritos celulares foram identificados 96 horas após o tratamento. Os resultados indicaram que a espermatogênese parasitária foi severamente afetada pelo albendazol e demonstrou a importância do uso da histopatologia para o diagnóstico de eficácia terapêutica em cepas de campo.

"Liver fluke": conceptos actuales sobre fascioliasis / Liver fluke: update on fascioliasis

Fascioliasis is a parasitic disease produced mainly by the fluke Fasciola hepatica. The human infection is mainly due to the accidental intake of metacercariae present in watercress and/or contaminated water. The human disease is uncommon in Chile, despite the high prevalence of animal infection, which affects almost the entire national territory and determines high economic and productive impacts. Human fascioliasis can manifest like acute or chronic phase of the disease (in Chile, the majority in chronic phase) and its identification requires a high index of suspicion, in individuals with abdominal pain, hepatomegaly and eosinophilia, where the epidemiological background of watercress ingestion is usually present. Diagnosis usually requires the integration of egg visualization in stools, serology and imaging studies. The treatment of choice with triclabendazole is usually highly effective and safe.

La fascioliasis es una enfermedad parasitaria producida principalmente por el trematodo Fasciola hepática. La infección en el hombre, quien es un huésped accidental, se debe principalmente a la ingesta de metacercarias presentes en berros y/o aguas contaminadas. La enfermedad en humanos es infrecuente en Chile, a pesar de la alta prevalencia de infección animal, que afecta a casi todo el territorio nacional y determina un alto impacto económico y productivo. La fascioliasis humana puede manifestarse en fase aguda o crónica (en Chile, la mayoría en fase crónica) y su identificación requiere un alto índice de sospecha, en individuos con dolor abdominal, hepatomegalia y eosinofilia, donde el antecedente epidemiológico de ingesta de berros suele estar presente. El diagnóstico, habitualmente requiere la integración de la visualización directa de huevos en las deposiciones, estudios de serología e imágenes. El tratamiento de elección con triclabendazol, habitualmente es altamente efectivo y seguro.

Pseudotumor inflamatorio por Fasciola hepática: a propósito de un caso / Inflammatory pseudotumor by Fasciola hepática: a case report

Introduction: Fasciola hepatica is a parasite of the class Trematoda. It commonly has been found in developing countries. When it infects humans is characterized by a triad of fever, pain in right upper quadrant and peripheral eosinophilia. We present a 67-year-old female from a rural town of the north of Lima, Peru, it was found abdominal pain, eosinophilia and focal hepatic lesions. For this reason, a hepatic mass was the initial suspicion. The hepatic biopsy was performed and one of the findings was eosinophilia. Fasciola hepatica infection should be considered as part of differential diagnosis in hepatic tumors with eosinophilia when the origin of the patient is from endemic areas of F. hepatica.

Fasciola hepática es un parásito de la clase Trematoda común en países en desarrollo. La infección en el ser humano se caracteriza por la triada de fiebre, dolor abdominal en el cuadrante superior derecho y eosinofilia. Se presenta el caso de una mujer de 67 años procedente de una zona rural al norte de Lima, con historia de dolor abdominal de seis meses de evolución, con una imagen hipodensa hepática en el TAC abdominal y eosinofilia. La biopsia hepática mostró un infiltrado inflamatorio con eosinofilia. En el diagnóstico diferencial en pacientes con un tumor hepático y eosinofilia, se deben incluir infecciones parasitarias como F. hepatica; sobre todo en pacientes que proceden de áreas endémicas.

Efficacy and tolerability of two single-day regimens of triclabendazole for fascioliasis in Peruvian children

The therapeutic scheme of triclabendazole (TCBZ), the recommended anthelmintic against Fasciola hepatica , involves 10mg/kg of body weight administered in a single dose; however, clinical trials in children are scarce. We evaluated the efficacy and tolerability of 2 schemes of TCBZ.

Fascioliasis hepática humana: resistencia al tratamiento con triclabendazol / Resistant human fasciolasis: Report of four patients

Human fascioliasis is a parasitic zoonosis that affects the liver of human and herbivorous animals. In chronic cases, its diagnosis is confirmed by direct visualization of parasitic eggs in stool examination, by positive testing for Fasciola hepatica antigens in stools, or by direct observation of parasites by endoscopic retrograde cholangiography or surgery. In acute cases, serological reactions as immunoblothing or detection of parasite antigens in the blood are useful. The treatment of choice is triclabendazole. However, parasite resistance in animals, as well as in man, has been reported to this drug. We report four patients in whom the parasitic infection persisted despite a course of treatment with triclabendazole.

Fasciolosis aguda: presentación de un caso de Cuba / Acute fasciolosis: a Cuban case report

Fasciolosis is a worldwide parasitic disease in human and domestic animals. The causative agents of fasciolosis are Fasciola hepatica and Fasciola gigantica but, in Cuba, only F. hepatica has been notified. As others neglected diseases, F. hepatica is more common in people living in rural areas where infected animals, intermediate hosts and susceptible hosts coexist. We describe the clinical features of a case that could contribute to the process of continuing medical education of health professionals in our geographic area.

Fasciolosis es una enfermedad parasitaria de humanos y diferentes animales. Sus agentes causales son Fasciola hepatica y Fasciola gigantica; sin embargo, en Cuba, solo la primera de esas especies ha sido notificada. Como otras enfermedades incorporadas en el grupo de las olvidadas o desatendidas, fasciolosis, es más frecuente en personas que viven en áreas rurales donde coexisten animales infectados, hospederos intermediarios y hospederos susceptibles. Se exponen las características de un caso que pudiera contribuir en el proceso de educación continuada de los profesionales de la salud en nuestra área geográfica.

Fascioliasis, revisión clínico-epidemiológica y diagnóstico / Fascioliasis, clinical-epidemiological review and diagnosis

La fascioliasis es una infección parasitaria causada por trematodos del género Fasciola, y la especie más frecuente es Fasciola hepatica, la cual se encuentra distribuida en todos los continentes e infecta a gran cantidad de mamíferos, incluyendo al hombre. Este trematodo requiere, para completar su ciclo de vida, de un hospedero intermediario, representado por un molusco que pertenece a la familia Lymnaeidae. En Cuba se conocen dos especies: Fossaria cubensis y Pseudosuccinea columella. Las manifestaciones clínicas son inespecíficas y varían de acuerdo con la fase de la enfermedad, aguda, latente o crónica. El diagnóstico de certeza de la fascioliasis humana se basa en el hallazgo de los huevos del parásito en las heces o en el fluido duodenal del individuo parasitado. Pero se han desarrollado otros métodos inmunoenzimáticos que han permitido un mayor acercamiento al diagnóstico de esta entidad. La situación epidemiológica de esta parasitosis ha cambiado en los últimos años. Desde 1980 el número de notificaciones de personas infectadas ha aumentado considerablemente en varias zonas. En Cuba se comporta como una enfermedad enzoótica del ganado bovino y es responsable de importantes pérdidas en las industrias pecuarias y alimenticias lo que nos permite considerarla como la enfermedad zoonótica de mayor importancia económica y de gran interés médico veterinario. Anualmente se diagnostican casos humanos en forma de brotes o casos esporádicos, por lo que cada día más se refuerza la necesidad de que se le brinde atención a la prevención y diagnóstico de esta parasitosis

The fascioliasis is a parasitic infection caused by tremadotes of Fasciola genre and the more frequent species is Fasciola hepatica which is distributed in all continents and to infecting many mammals, including the man. To complete its life cycle, this trematode needs an intermediate host, represented by a mollusk from Lymnaeidae family. In Cuba two species are known: Fossaria cubensis and Pseudosuccinea columella. The clinical manifestations are not specific and varied according to the disease phase, acute, latent or chronic. The certainty diagnosis of the human fascioliasis is based in the finding that the parasite eggs present in feces or in duodenal fluid of parasitized individual. Other immuno-enzymatic methods have been developed allowing a great approaching to diagnosis of this entity. The epidemiological situation of this parasitosis has change in past years. From 1980 the figure of notifications of infected persons has significantly increase in some zones. In Cuba it behaves as an enzootic disease of bovine cattle and account for many loss in livestock and food industries allowing to consider it as a zoonotic disease a great economic significance and of great medical-veterinary interest. Yearly human cases are diagnosed like outbreaks or sporadic cases, thus each day the need of attention to prevention and diagnosis of this parasitosis is reinforced

Comportamiento clínico-terapéutico de Fasciola hepatica en una serie de 87 pacientes / Clinical and therapeutic behaviour of Fasciola hepatica in a series of 87 patients

Introducción: la fasciolosis, por Fasciola hepatica, muestra a escala mundial un incremento en la incidencia de enfermos en los últimos años. Cuba se encuentra entre aquellos países donde se reportan casos esporádicos y algunos brotes epidémicos. Objetivo: describir el comportamiento clínico-terapéutico de esta trematodiosis de trasmisión digestiva en una serie de 87 pacientes ingresados en el Instituto de Medicina Tropical "Pedro Kourí" desde enero de 1996 a diciembre de 2005. Método: los pacientes se dividieron en 2 grupos atendiendo al fármaco prescrito, dihidroemetina o triclabendazol. Se recogieron las variables clínicas al inicio del diagnóstico y 90 d después del tratamiento; se hallaron las medias y la desviación estándar. Resultados: el sexo masculino predominó discretamente con 54 por ciento en nuestra serie de pacientes ingresados en el servicio de medicina tropical del instituto. La ingestión de berro (Nasturtium officinale) estuvo presente en casi la mitad de los pacientes. El dolor abdominal, fiebre y astenia resultaron los síntomas de mayor frecuencia. El triclabendazol y la dihidroemetina fueron útiles en el tratamiento. Conclusiones: se comprobó la utilidad de los exámenes de laboratorio en el diagnóstico y seguimiento de los enfermos. Los antiparasitarios dihidroemetina y triclabendazol resultaron efectivos a las dosis utilizadas con efectos adversos menores.

Introduction: in the last few years, the Incidence rate of fascioliosis caused by Fasciola hepatica has increased worldwide. Cuba is one of the countries that have reported sporadic cases and also some outbreaks of fasciolosis. Objective: to describe clinical and therapeutic features of this trematodiasis of digestive transmission found in 87 patients, who had been admitted to "Pedro Kourí" Institute of Tropical Medicine from January 1996 to December 2005. Methods: patients were divided into 2 groups according to the prescribed drug, that is, triclabendazole and dihydroemetine. The clinical variables were collected at the time of diagnosis and 90 days after treatment; the means and the standard deviation were estimated. Results: males was slightly predominant (54) in our series of patients admitted to the institute service. Consumption of watercress (Nasturtium officinale) was found in almost half of the patients. Abdominal pain, fever and malaise were the most frequent symptoms. Both drugs were useful to treat F. hepatica. Conclusions: this study showed the usefulness of lab tests for diagnosis and follow-up of patients after treatment. The anti-parasitic drugs dihydroemetine and triclabendazole proved to be effective at the prescribed doses in this research with minor adverse effects.

Evaluation of two doses of triclabendazole in treatment of patients with combined schistosomiasis and fascioliasis

To determine the safety and efficacy of 2 consecutive doses of triclabendazole [TCBZ] in the treatment of Schistosoma mansoni infection in human cases infected with both S. mansoni and Fasdola spv we conducted afield survey involving 6314 individuals from 15 villages. The overall prevalence of schistosomiasis alone was 15.8%, of fascioliasis alone 2.2%, and of combined infection 0.7%. Treatment with 2 doses of TCBZ was given to the 49 cases with combined infection. Eight weeks after treatment, the cure rate was 96% for fascioliasis and was 32.7% for schistosorniasis. All schistosomiasis cases cured had a low intensity infection. Liver function tests done before I treatment and 8 weeks after substantiate the safety of 2 doses of TCBZ given to those with combined infection. Administration of TCBZ should precede praziquantel in treatment of combined infection, however TCBZ cannot be recommended for infection with S. mansoni alone

A Case of Biliary Fascioliasis by Fasciola gigantica in Turkey

A case of Fasciola gigantica-induced biliary obstruction and cholestasis is reported in Turkey. The patient was a 37- year-old woman, and suffered from icterus, ascites, and pain in her right upper abdominal region. A total of 7 living adult flukes were recovered during endoscopic retrograde cholangiopancreatography (ERCP). A single dose of triclabendazole was administered to treat possible remaining worms. She was living in a village of southeast of Anatolia region and had sheeps and cows. She had the history of eating lettuce, mallow, dill, and parsley without washing. This is the first case of fascioliasis which was treated via endoscopic biliary extraction during ERCP in Turkey.

A short review of the anthelmintic role of mirazid / Breve revisão sobre a ação anti-helmíntica do mirazid

Mirazid® is a patented preparation from a plant that had been used in folk medicine since ancient Egyptians (Myrrh). It was registered in Egypt for the treatment of schistosomiasis and fascioliasis. Over 32 independent studies for efficacy of Mirazid had been reviewed and their results analyzed. The majority of these studies reported higher than 90 percent cure rates, that even higher in mixed than single trematodal infections in humans and in farm animals. Only two groups of investigators reported lower cure rates as they used lower doses and estimated cure rates at a shorter period from treatment than recommended by innovators.

Mirazid® é um produto patenteado preparado a partir de planta usada na medicina popular desde o Egito antigo conhecida como Mirra. Está registrada no Egito para o tratamento da esquistossomose e da fasciolíase. Foram revistos 32 estudos independentes sobre a eficácia do mirazid e seus resultados analisados. A maioria destes estudos reporta mais de 90 por cento de índice de cura, tanto em infecções mistas por trematódeos em humanos como em animais rurais. Apenas dois grupos de investigadores tiveram baixos índices de cura, mas usaram baixas doses e períodos curtos de tratamento, diferente do recomendado pelos precursores.

Fascioliasis hepática / Hepatic fascioliasis

La fascioliasis hepática es una enfermedad parasitaria infecciosa producida por el trematodo Fasciola hepática. El humano es infectado accidentalmente al ingerir vegetales (principalmente berros) contaminados con las formas enquistadas del parásito (metacercarias). Clínicamente se reconoce una fase hepática (fase aguda) que comprende desde la liberación de la larva en el duodeno hasta su llegada a la vía biliar, y una fase biliar (fase crónica), en donde la Fasciola se localiza en la vía biliar, madura a su forma adulta y produce huevos. El diagnóstico requiere un alto índice de sospecha dado el polimorfismo en la presentación y muchas veces el desconocimiento de antecedentes epidemiológicos. Las manifestaciones clínicas dependen del período en el cual se encuentra la enfermedad, sin embargo, lo más habitual es la presencia de dolor abdominal y eosinofilia. El diagnóstico definitivo requiere la demostración del parásito a través de métodos directos (visualización por medio de colangiografía retrógrada endoscópica o búsqueda de huevos en deposiciones o bilis) o a través de la demostración por métodos serológicos. El tratamiento actualmente disponible con triclabendazol es altamente efectivo.

The hepatic fascioliasis is a parasitic disease caused by infectious trematode fasciola hepática. Man is infected accidentally by ingesting vegetables (mainly watercress) contaminated with the parasite encysted forms (metacercariae). Clinically a hepatic phase (acute phase) is recognized, ranging from the release of the larvae in the duodenum to their arrival to the bile duct and a bile phase (chronic phase), where fasciola is located in the bile duct, and the parasite matures to the adult form and produces eggs. The diagnosis requires a high index of suspicion given the polymorphism in the presentation and the frequent lack of epidemiological history. The clinical manifestations depend on the current period of the disease is, however, the most common is the presence of abdominal pain and eosinophilia. Definitive diagnosis requires demonstration of the parasite through direct methods (visualization by ERCP or search for eggs in stool or bile), or through the demonstration by serological methods. The currently available treatment is highly effective with triclabendazole.

Ineffectiveness of myrrh-derivative Mirazid against schistosomiasis and fascioliasis in humans

The present study assessed the schistosomicidal and fasciolicidal actions of the myrrh-derivative Mirazid in an area of low schistosomiasis transmission. A total of 27 patients infected with Schistosoma mansoni and 16 with Fasciola spp. received the maximum recommended dose of Mirazid. Pretreatment egg counts in 4 Kato-Katz slides were compared with similar counts in stool samples collected 1 and 2 months after treatment. Standard procedures and quality control measures were followed. The results revealed that Mirazid used as schistosomicidal or fasciolicidal agent in the maximum recommended dose has a low cure rate and produced a negligible reduction in egg counts. Prescribing such an ineffective drug in Egypt might endanger the achievements of the schistosomiasis control strategy

Fasciolasis hepática: enfermedad con múltiples presentaciones / Hepatic fascioliasis: a disease with multiple presentations

Human Fascioliasis is a zoonosis produced by the liver fluke fasciola. Its diagnosisrequires a high index of suspicion because of the polymorphism in its presentation. However, treatment with triclabendazole is highly effective. We report three cases that, in spite off presenting with diverse clinical severity, all had good response to treatment. Patient 1 presented with nonspecific recurrent abdominal pain with a normal CT scan of abdomen. Patient 2 presented with an abdominal CT scan showing multiple hepatic nodules. Patient 3 with an asymptomatic liver tumor requiring a comprehensive and expensive evaluation. All had eosinophilia and all responded to triclabendazole therapy without adverse effects.

La fasciolasis humana es una zoonosis producida por el trematodo fasciola hepática. Su diagnóstico requiere un alto índice de sospecha dado el polimorfismo en su presentación. Pese a esto, el tratamiento con triclabendazol es muy efectivo. Se reportan tres casos clínicos que, pese a presentar muy distinta clínica y gravedad, todos tuvieron buena respuesta al tratamiento con Triclabendazol. El paciente 1 se presentó con dolor abdominal inespecífico y recurrente, sin compromiso del estado general con tomografía de abdomen normal. La paciente 2 presentó dolor abdominal intenso, baja de peso y gran compromiso del estado general que requirió hospitalización, con tomografía de abdomen que mostró lesiones nodulares hepáticas. La paciente 3 se presentó como hallazgo de tumor hepático asintomático que requirió amplio estudio y grandes costos. Todos presentaron eosinofilia y todos respondieron a terapia con triclabendazol sin efectos adversos.

Parásitos de fasciola hepática intracoledociano / Common bile duct fasciolasis: report of one case

La fasciolasis es una enfermedad parasitaria producida por el tremátodo digeneo Fasciola hepática. Durante la fase crónica de la enfermedad los parásitos pueden entran en los conductos biliares, y ser causa de ictericia obstructiva, colangitis, pancreatitis y otras complicaciones. Se presenta el caso clínico de una paciente intervenida por sospecha de colelitiasis y colédocolitiasis, a la cual durante la exploración coledociana intraoperatoria le fueron extraídos múltiples parásitos adultos de Fasciola hepática. Este hallazgo sólo fue aclarado posteriormente en la biopsia diferida. Se realiza una revisión breve del tema, métodos de diagnóstico, tratamiento médico y alternativas quirúrgicas de tratamiento.

Fasciolasis is a zoonotic disease caused by the digenean trematode Fasciola hepatica. During the chronic phase of the disease the parasites invade the main biliary ducts, causing obstructive jaundice, cholangitis, pancreatitis and other complications. We report a 75 years old female, operated due to the suspicion of a choledocholithiasis. During the exploration of the choledochus, adult F. hepatica parasites were extracted. The pathology report of the parasites confirmed the diagnosis.

Fascioliasis in relatives of patients with Fasciola hepatica infection in Peru

Altas tasas de fasciolosis humana han sido descritas en varias regiones del Perú. Estudiamos 20 familias en una área endémica del Perú para determinar la proporción de infección con F. hepatica en los familiares de los sujetos diagnosticados y para identificar factores de riesgo asociados. El estudio incluyó un total de 93 sujetos, quienes contribuyeron con muestras de heces y sangre. Las edades comprendieron desde 1 a 53 años (media = 18.6; DS = 14.2). La prevalencia general de fasciolosis por exámenes de heces fue 33.3% (n = 83) y por serología, 51.9% (n = 86). La prevalencia en el grupo de edad I (< 19 años de edad) por pruebas coprológicas y serológicas fueron 61.4% y 75.9%, respectivamente; en el grupo II (> 19 años de edad) 15.4% y 37.5%. El principal factor de riesgo asociado con fasciolosis fue comer ensaladas (OR = 3.29, IC = 1.2-9.0, p = 0.02). En conclusión, la fasciolosis humana es altamente prevalente en familiares de los casos índices y el factor de riesgo más significante para adquirirla en la familia es comer ensaladas en las áreas endémicas.

Fasciolíase: relato de dois casos em área rural do Rio de Janeiro / Fascioliasis: report of two cases from rural areas of Rio de Janeiro

São descritos dois casos de fasciolíase em áreas rurais do Rio de Janeiro, endêmicas para esquistossomose, sendo ambos surpreendidos durante inquéritos coprológicos. O paciente de Paracambi queixava-se de tonteira. A paciente de Sumidouro queixava-se de tonteira, cansaço e tosse, tendo sido tratada com praziquantel; seus exames de controle foram negativos.

Study of cytogenetic biomarkers in human fascioliasis and triclabendazole treatment

The cytogenetic effect of triclabendazole, an anti-helminthic drug used for the treatment of human fascioliasis, was evaluated in the peripheral blood lymphocytes of 30 patients with Fasciola hepatica before and after treatment with the drug. The number of cells with chromosomal aberrations and sister chromatid exchanges did not show any statistically significant differences in the patients, either before treatment when compared with the control or after triclabendazole therapy. Based on the results of the present study, data indicated that infection with Fasciola hepatica does not increase the chromosomal aberrations or sister chromatid exchanges and the genotoxic effect of triclabendazole indicated that the drug is not a mutagenic agent and could be used safely in therapeutic doses for the treatment of human fascioliasis